According to the FDA guidelines every newly synthesized drug should be enantiopure. To address this issue, we are developing new chiral ligands and catalytic methods by which we can induce chirality in desired fashion with very high efficiency. We are working in the interface of organocatalysis, transition-metal catalysis and metalloradical catalysis.

Asrar Ahmad
Ph.D.scholar